Lv7
5000 积分 2023-08-23 加入
Abstract LB055: IBI3001: A potentially first-in-class site-specifically conjugated B7-H3/EGFR bispecific ADC for multiple solid tumors
1个月前
已完结
Modular in vivo antibody–ADC click to reverse drug resistance in tumours
1个月前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
4个月前
已完结
The Recent Developments of ADCs with the Tubulysins as the Payloads
11个月前
已完结
379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study
1年前
已完结
Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study
1年前
已完结
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
1年前
已完结
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer
1年前
已完结
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
1年前
已完结
Immunogenic cell death in cancer and infectious disease
1年前
已完结
皖公网安备34019202002308
